Across TCGA pan-cancer cohorts, AFMID mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AFMID data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AFMID mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated AFMID expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where AFMID mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	1.000	0.752	.002	61	view →
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	6	view →
PDAC	DFS	Median	IV	0.749	0.217	.024	5	view →
LUAD	DFS	Quartile	II,III,IV	0.308	0.735	.022	3	view →
GBM	OS	Quartile	All	0.258	0.675	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: AFMID tumor-vs-normal RNA expression · all AFMID data types